Skip to main content

The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.

Publication ,  Journal Article
Zhang, T; Armstrong, AJ
Published in: J Clin Oncol
October 1, 2017

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

October 1, 2017

Volume

35

Issue

28

Start / End Page

3175 / 3177

Location

United States

Related Subject Headings

  • Taxoids
  • Prostatic Neoplasms, Castration-Resistant
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Docetaxel
  • Biomarkers
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, T., & Armstrong, A. J. (2017). The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol, 35(28), 3175–3177. https://doi.org/10.1200/JCO.2017.74.7931
Zhang, Tian, and Andrew J. Armstrong. “The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.J Clin Oncol 35, no. 28 (October 1, 2017): 3175–77. https://doi.org/10.1200/JCO.2017.74.7931.
Zhang, Tian, and Andrew J. Armstrong. “The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.J Clin Oncol, vol. 35, no. 28, Oct. 2017, pp. 3175–77. Pubmed, doi:10.1200/JCO.2017.74.7931.
Zhang T, Armstrong AJ. The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2017 Oct 1;35(28):3175–3177.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

October 1, 2017

Volume

35

Issue

28

Start / End Page

3175 / 3177

Location

United States

Related Subject Headings

  • Taxoids
  • Prostatic Neoplasms, Castration-Resistant
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Docetaxel
  • Biomarkers
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences